Кфар-Малал: Израильдің орталық аймағындағы мошав тарихы

Moshav in central Israel

Kfar Malal is a moshav in central Israel. Located in the Sharon plain, it falls under the jurisdiction of Drom HaSharon Regional Council. In it had a population of .

Before the 20th century the area formed part of the Forest of Sharon. It was an open woodland dominated by Mount Tabor Oak, which extended from Kfar Yona in the north to Ra'anana in the south. The local Arab inhabitants traditionally used the area for pasture, firewood and intermittent cultivation. The intensification of settlement and agriculture in the coastal plain during the 19th century led to deforestation and subsequent environmental degradation. The village was established in 1911 as "Ein Hai" (lit. Fountain of the Living) on privately owned land. The original name was based on the name of ruins previously located there, Khurbet el Haiyeh. In 1914 the village was renamed into Kfar Malal after Moshe Leib Lilienblum, an early leader of the Hovevei Zion movement, whose acronym in Hebrew is MLL (מל"ל). The village was destroyed in the battles of World War I, resettled by a group of laborers and ravaged again in the 1921 Jaffa riots. More information in The remnants of the historic Moshava in Kfar Malal. In 1922, the land was transferred to the Jewish National Fund and Kfar Malal was rebuilt as a moshav. It suffered more attacks in the 1929 Palestine riots. He also recalled that his mother slept with a rifle under her bed until her dying day due to the trauma of hiding in the cowshed with her children at night to escape roving Bedouin gangs.

In 2006 Malal Park Industries Ltd, co owned by members of Kfar Malal, signed an agreement with the German bank Eurohypo AG to refinance Park Azorim in Kiryat Aryeh, Petah Tikva. In 2009 NI Medical, a biotech company located in Kfar Malal, received approval by the U. S. Food and Drug Administration (FDA) for a device that assesses left ventricular systolic dysfunction (LVSD). The device aids physicians in detecting heart failure in its pre clinical, asymptomatic phase.